Literature DB >> 23486868

Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution.

Lucy Matthews1, Rita Marasco, Mark Jenkinson, Wilhelm Küker, Sebastian Luppe, Maria Isabel Leite, Antonio Giorgio, Nicola De Stefano, Neil Robertson, Heidi Johansen-Berg, Nikos Evangelou, Jacqueline Palace.   

Abstract

OBJECTIVE: Neuromyelitis optica and its spectrum disorder (NMOSD) can present similarly to relapsing-remitting multiple sclerosis (RRMS). Using a quantitative lesion mapping approach, this research aimed to identify differences in MRI brain lesion distribution between aquaporin-4 antibody-positive NMOSD and RRMS, and to test their diagnostic potential.
METHODS: Clinical brain MRI sequences for 44 patients with aquaporin-4 antibody-positive NMOSD and 50 patients with RRMS were examined for the distribution and morphology of brain lesions. T2 lesion maps were created for each subject allowing the quantitative comparison of the 2 conditions with lesion probability and voxel-wise analysis.
RESULTS: Sixty-three percent of patients with NMOSD had brain lesions and of these 27% were diagnostic of multiple sclerosis. Patients with RRMS were significantly more likely to have lesions adjacent to the body of the lateral ventricle than patients with NMOSD. Direct comparison of the probability distributions and the morphologic attributes of the lesions in each group identified criteria of "at least 1 lesion adjacent to the body of the lateral ventricle and in the inferior temporal lobe; or the presence of a subcortical U-fiber lesion; or a Dawson's finger-type lesion," which could distinguish patients with multiple sclerosis from those with NMOSD with 92% sensitivity, 96% specificity, 98% positive predictive value, and 86% negative predictive value.
CONCLUSION: Careful inspection of the distribution and morphology of MRI brain lesions can distinguish RRMS and NMOSD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23486868      PMCID: PMC3656462          DOI: 10.1212/WNL.0b013e3182887957

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  23 in total

1.  The clinical course of neuromyelitis optica (Devic's syndrome).

Authors:  D M Wingerchuk; W F Hogancamp; P C O'Brien; B G Weinshenker
Journal:  Neurology       Date:  1999-09-22       Impact factor: 9.910

2.  Improved optimization for the robust and accurate linear registration and motion correction of brain images.

Authors:  Mark Jenkinson; Peter Bannister; Michael Brady; Stephen Smith
Journal:  Neuroimage       Date:  2002-10       Impact factor: 6.556

Review 3.  Advances in functional and structural MR image analysis and implementation as FSL.

Authors:  Stephen M Smith; Mark Jenkinson; Mark W Woolrich; Christian F Beckmann; Timothy E J Behrens; Heidi Johansen-Berg; Peter R Bannister; Marilena De Luca; Ivana Drobnjak; David E Flitney; Rami K Niazy; James Saunders; John Vickers; Yongyue Zhang; Nicola De Stefano; J Michael Brady; Paul M Matthews
Journal:  Neuroimage       Date:  2004       Impact factor: 6.556

4.  Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression.

Authors:  Sean J Pittock; Brian G Weinshenker; Claudia F Lucchinetti; Dean M Wingerchuk; John R Corboy; Vanda A Lennon
Journal:  Arch Neurol       Date:  2006-07

5.  A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.

Authors:  Vanda A Lennon; Dean M Wingerchuk; Thomas J Kryzer; Sean J Pittock; Claudia F Lucchinetti; Kazuo Fujihara; Ichiro Nakashima; Brian G Weinshenker
Journal:  Lancet       Date:  2004 Dec 11-17       Impact factor: 79.321

6.  Revised diagnostic criteria for neuromyelitis optica.

Authors:  D M Wingerchuk; V A Lennon; S J Pittock; C F Lucchinetti; B G Weinshenker
Journal:  Neurology       Date:  2006-05-23       Impact factor: 9.910

7.  Brain abnormalities in neuromyelitis optica.

Authors:  Sean J Pittock; Vanda A Lennon; Karl Krecke; Dean M Wingerchuk; Claudia F Lucchinetti; Brian G Weinshenker
Journal:  Arch Neurol       Date:  2006-03

8.  Spatial mapping of T2 and gadolinium-enhancing T1 lesion volumes in multiple sclerosis: evidence for distinct mechanisms of lesion genesis?

Authors:  M A Lee; S Smith; J Palace; S Narayanan; N Silver; L Minicucci; M Filippi; D H Miller; D L Arnold; P M Matthews
Journal:  Brain       Date:  1999-07       Impact factor: 13.501

Review 9.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".

Authors:  Chris H Polman; Stephen C Reingold; Gilles Edan; Massimo Filippi; Hans-Peter Hartung; Ludwig Kappos; Fred D Lublin; Luanne M Metz; Henry F McFarland; Paul W O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Brian G Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2005-12       Impact factor: 10.422

10.  IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel.

Authors:  Vanda A Lennon; Thomas J Kryzer; Sean J Pittock; A S Verkman; Shannon R Hinson
Journal:  J Exp Med       Date:  2005-08-08       Impact factor: 14.307

View more
  57 in total

1.  Neuromyelitis optica presenting as intractable vomiting and hyperCKaemia.

Authors:  Tarig Mohammed Abkur; Eílis Foran; Hugh Kearney; Grace Harkin; Valerie Byrnes; John Lynch
Journal:  J Neurol       Date:  2015-11-21       Impact factor: 4.849

2.  Natalizumab and the development of extensive brain lesions in neuromyelitis optica.

Authors:  Maciej Juryńczyk; Krzysztof Zaleski; Krzysztof Selmaj
Journal:  J Neurol       Date:  2013-05-30       Impact factor: 4.849

3.  Late AQP4-IgG seroconversion and shrinking of brainstem MRI lesions in a patient with overlapping CIS/NMOSD.

Authors:  E Giorli; D Franciotta; A Beronio; C Amodeo; S Delucchi; S Boni; C Serrati; A Mannironi; L Benedetti
Journal:  J Neurol       Date:  2016-11-04       Impact factor: 4.849

Review 4.  [MOG encephalomyelitis: international recommendations on diagnosis and antibody testing].

Authors:  S Jarius; F Paul; O Aktas; N Asgari; R C Dale; J de Seze; D Franciotta; K Fujihara; A Jacob; H J Kim; I Kleiter; T Kümpfel; M Levy; J Palace; K Ruprecht; A Saiz; C Trebst; B G Weinshenker; B Wildemann
Journal:  Nervenarzt       Date:  2018-12       Impact factor: 1.214

Review 5.  Neuromyelitis Optica (Devic's Syndrome): an Appraisal.

Authors:  Teresa M Crout; Laura P Parks; Vikas Majithia
Journal:  Curr Rheumatol Rep       Date:  2016-08       Impact factor: 4.592

Review 6.  The current role of MRI in differentiating multiple sclerosis from its imaging mimics.

Authors:  Ruth Geraldes; Olga Ciccarelli; Frederik Barkhof; Nicola De Stefano; Christian Enzinger; Massimo Filippi; Monika Hofer; Friedemann Paul; Paolo Preziosa; Alex Rovira; Gabriele C DeLuca; Ludwig Kappos; Tarek Yousry; Franz Fazekas; Jette Frederiksen; Claudio Gasperini; Jaume Sastre-Garriga; Nikos Evangelou; Jacqueline Palace
Journal:  Nat Rev Neurol       Date:  2018-03-09       Impact factor: 42.937

7.  Quantitative brain lesion distribution may distinguish MOG-ab and AQP4-ab neuromyelitis optica spectrum disorders.

Authors:  Liqin Yang; Haiqing Li; Wei Xia; Chao Quan; Lei Zhou; Daoying Geng; Yuxin Li
Journal:  Eur Radiol       Date:  2019-11-20       Impact factor: 5.315

8.  Multifrequency magnetic resonance elastography of the brain reveals tissue degeneration in neuromyelitis optica spectrum disorder.

Authors:  Kaspar-Josche Streitberger; Andreas Fehlner; Florence Pache; Anna Lacheta; Sebastian Papazoglou; Judith Bellmann-Strobl; Klemens Ruprecht; Alexander Brandt; Jürgen Braun; Ingolf Sack; Friedemann Paul; Jens Wuerfel
Journal:  Eur Radiol       Date:  2016-08-29       Impact factor: 5.315

Review 9.  What do we know about brain contrast enhancement patterns in neuromyelitis optica?

Authors:  Yeliz Pekcevik; Gunes Orman; In Ho Lee; Maureen A Mealy; Michael Levy; Izlem Izbudak
Journal:  Clin Imaging       Date:  2015-07-26       Impact factor: 1.605

Review 10.  What's new in neuromyelitis optica? A short review for the clinical neurologist.

Authors:  Daniel Whittam; Martin Wilson; Shahd Hamid; Geoff Keir; Maneesh Bhojak; Anu Jacob
Journal:  J Neurol       Date:  2017-03-13       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.